Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M294,467Revenue $M71,312Net Margin (%)23.3Z-Score5.6
Enterprise Value $M276,729EPS $4.8Operating Margin %28.1F-Score7
P/E(ttm))17.5Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book3.810-y EBITDA Growth Rate %3.5Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-0.9Current Ratio2.6Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %23.6ROA % (ttm)13.1Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)23.1Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M2,799ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 104.591%New holding, 14319 sh.14,319
JNJRay Dalio 2014-09-30 Add0.02%$99.82 - $108.64
($103.64)
$ 104.591%Add 27.77%84,193
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 104.591%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 104.591%Reduce -99.8%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 104.591%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 104.591%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 104.591%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 104.591%Reduce -3.7%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 104.591%Sold Out0
JNJJohn Rogers 2014-06-30 Add0.2%$96.54 - $105.76
($101.02)
$ 104.594%Add 42.46%522,727
JNJRichard Pzena 2014-06-30 Add0.17%$96.54 - $105.76
($101.02)
$ 104.594%Add 33.12%1,155,666
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -13.16%3,300,000
JNJRobert Olstein 2014-06-30 Reduce-0.31%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -20.91%87,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -5.5%9,045,902
JNJTweedy Browne 2014-06-30 Reduce-0.17%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -1.71%4,196,224
JNJRay Dalio 2014-06-30 Reduce-0.16%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -74.94%65,893
JNJGeorge Soros 2014-06-30 Reduce-0.05%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -51.22%50,000
JNJJoel Greenblatt 2014-06-30 Sold Out -0.01%$96.54 - $105.76
($101.02)
$ 104.594%Sold Out0
JNJJohn Hussman 2014-06-30 Reduce-0.01%$96.54 - $105.76
($101.02)
$ 104.594%Reduce -50%1,325
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:


News about JNJ:

Articles On GuruFocus.com
NASDAQ Dividend Achievers: Deere & Company Dec 19 2014 
Is Johnson & Johnson Still A Worthy Buy? Dec 18 2014 
Why I Sold American Realty Capital Properties Dec 17 2014 
Boston Scientific Lost the First Place in Innovation Dec 11 2014 
Dividends vs. Stock Buybacks Dec 09 2014 
Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
test_app_3 Nov 28 2014 
test_app_3 Nov 28 2014 
test_app_2 Nov 28 2014 
test_app Nov 28 2014 


More From Other Websites
Business Highlights Dec 24 2014
Tuesday’s Notable Options Activity: Bio Hazzard Dec 24 2014
Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 Dec 24 2014
Buy biotech dip? Dec 23 2014
Indexes Turn Mixed On Data; Celgene Dives Dec 23 2014
IPO Stock Watch: Medical Device Maker Nevro Hits High Dec 22 2014
Inside AbbVie's exclusive deal Dec 22 2014
MacroGenics Partners With J&J; Stock Jumps Dec 22 2014
Express Scripts Picks AbbVie HCV Drugs Over Gilead Dec 22 2014
Express Scripts selects AbbVie over Gilead Dec 22 2014
Express Scripts gets deal for AbbVie's hepatitis C drug Dec 22 2014
Beta-Amyloid: The Emperor Really Does Have No Clothes Dec 20 2014
Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant... Dec 19 2014
BTG's Dame Louise Makin builds fast-growing healthcare group Dec 18 2014
Johnson & Johnson to Host Fourth-Quarter/ Full-Year 2014 Investor Conference Call on Results Dec 17 2014
Johnson & Johnson to Host Fourth-Quarter/Full-Year 2014 Investor Conference Call on Results Dec 17 2014
Is This The Future Of Late-Stage Drug Development? Dec 15 2014
Sucampo Appoints John H. Johnson to Board of Directors Dec 15 2014
J&J Tuberculosis Drug Poised for Expanded Reach Dec 11 2014
Johnson & Johnson Announces Collaboration between Janssen and USAID to Expand Access to... Dec 11 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Gurufocus
ReplyGurufocus - 1 year ago
test
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK